This website uses cookies

Some cookies are strictly necessary for the proper functioning of the website. Therefore you cannot unclick the corresponding box if you wish to visit the website. Other cookies are used for statistics and marketing purposes. We will not place them unless you agree by ticking the corresponding box.

Cookies that the site cannot function properly without. This includes cookies for access to secure areas and CSRF security. Please note that Craft’s default cookies do not collect any personal or sensitive information. Craft's default cookies do not collect IP addresses. The information they store is not sent to Pixel & Tonic or any 3rd parties.
Name: CraftSessionId
Description: Craft relies on PHP sessions to maintain sessions across web requests. That is done via the PHP session cookie. Craft names that cookie “CraftSessionId” by default, but it can be renamed via the phpSessionId config setting. This cookie will expire as soon as the session expires.
Provider: this site
Expiry: Session
Name: *_identity
Description: When you log into the Control Panel, you will get an authentication cookie used to maintain your authenticated state. The cookie name is prefixed with a long, randomly generated string, followed by _identity. The cookie only stores information necessary to maintain a secure, authenticated session and will only exist for as long as the user is authenticated in Craft.
Provider: this site
Expiry: Persistent
Name: *_username
Description: If you check the "Keep me logged in" option during login, this cookie is used to remember the username for your next authentication.
Provider: this site
Expiry: Persistent
Name: CRAFT_CSRF_TOKEN
Description: Protects us and you as a user against Cross-Site Request Forgery attacks.
Provider: this site
Expiry: Session
Statistic cookies help us understand how visitors interact with websites by collecting and reporting information anonymously.
Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
Details Hide Details
COOKIES
  • Home
  • The Science
  • Nu.Q® Pipeline
    • Nu.Q®
    • Nu.Q® NETs
    • Nu.Q® Vet
    • Nu.Q® Capture
    • Nu.Q® Discover
  • About Us
    • Our Values
    • Our Expert Team
    • Careers
    • Contact Us
  • Investors
  • Resources
    • News Room
    • Scientific
    • Investors
    • Veterinary Resources
  • Join Mailing List
Volition
  • Home
  • The Science
  • Nu.Q® Pipeline
    • Nu.Q®
    • Nu.Q® NETs
    • Nu.Q® Vet
    • Nu.Q® Capture
    • Nu.Q® Discover
Volition
  • About Us
    • Our Values
    • Our Expert Team
    • Careers
    • Contact Us
  • Investors
  • Resources
    • News Room
      • Press Releases
      • In Focus
      • Video Gallery
      • Media Toolkit
      • Downloads
    • Scientific
      • Clinical Papers & Posters
      • Presentations
      • Video Gallery
    • Investors
      • Presentations
      • Video Gallery
    • Veterinary Resources
  • Join Mailing List
  1. Resources
  2. ᐳ
  3. Press Room ᐳ
  4. Press Releases
Press Releases In Focus Video Gallery Downloads Media Toolkit

Press Releases.

Jan 20, 2023 1:30pm

Volition to Take Part in Nu.Q® Vet Commercial Strategy Webinar

Jan 12, 2023 1:29pm

Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX's Reference Laboratory Network

Jan 08, 2023 5:00pm

Volition Issues Business Review 2022

Nov 14, 2022 9:10pm

VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update

Nov 14, 2022 1:30pm

Volition Announces Clinical Research Study with Oncovet

Nov 10, 2022 1:30pm

Volition to Participate in a Lung Cancer Screening Study in France

Nov 09, 2022 1:30pm

VolitionRx Limited Schedules Third Quarter 2022 Earnings Conference Call and Business Update

Nov 03, 2022 12:30pm

Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories

Oct 20, 2022 1:00pm

Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test

Aug 16, 2022 1:00pm

Volition Appoints Mickie Henshall as an Independent Director

Aug 10, 2022 9:10pm

VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business Update

Aug 10, 2022 1:00pm

Volition Announces U.S. Clinical Study for NETs

  • Contact Us
  • Downloads
  • eIFU Resources
  • Privacy Policy
  • Cookies Policy
  • Disclaimer
  • Manage Cookie Preferences
Sign up to email alerts
linkedin facebook twitter

The European Regional Development Fund and Wallonia are investing in your future

http://europe.wallonie.be

The European Regional Development Fund and Wallonia are investing in your future

http://europe.wallonie.be

MENAC - Epigenetic Modifications of Nucleosomes Associated with Cancer

Thanks to a grant of 1.990.798€ from the European Regional Development Fund and Walloon Government, we’re taking part in the MENAC project which aims to develop innovative non-invasive tests for the early detection of different types of cancer. We’re working in partnership with Synabs to create monoclonal antibodies and develop new diagnostic and theragnostic immunoassays.